Resultados e vida financeiraSaúde - Farmacêutica - Biotecnologia
Valneva Announces Positive Phase 2 Results for Tetravalent Shigella Vaccine Candidate S4V2
09/11/2026 07:00
AMFPublicação imediata
Data from infant immunogenicity and safety trial, and controlled human infection model (CHIM) trial, demonstrate favorable safety profile with encouraging immunogenicity and efficacy signals
VALNEVA SE
Îlot Saint-Joseph, Bureaux Convergence, Bât. A,
12 ter Quai Perrache
69002 Lyon, France
Valneva Announces Positive Phase 2 Results for Tetravalent
Shigella Vaccine Candidate S4V2
Data from infant immunogenicity and safety trial, and controlled human infection model (CHIM) trial, demonstrate favorable safety profile with encouraging immunogenicity and efficacy signals
Lyon (France), November 9, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced positive results from two Phase 2 trials of Shigella4V2 (S4V2), the world’s most clinically advanced tetravalent bioconjugate vaccine candidate against shigellosis. Valneva is evaluating the complete dataset of the Phase 2 infant and CHIM trials to determine the most appropriate path forward for the potential first-in-class vaccine candidate.
Shigellosis is the second leading cause of fatal diarrheal disease worldwide, strongly contributing to pediatric morbidity and mortality. It is estimated that up to 165 million infections annually are due to Shigella of which 62.3 million occur in children younger than five years1. Developing an effective vaccine to prevent this deadly disease is a public health imperative for many areas of the world.
The Phase 2 infant trial S4V02 (Identifier: NCT06523231) conducted in Kenya investigated the safety and immunogenicity of two dose levels of S4V2 compared with a control meningococcal vaccine in 110 infants aged nine months. Participants were vaccinated according to a two-dose schedule.
S4V2 showed a favorable safety and tolerability profile across both dose levels evaluated. Most solicited and unsolicited adverse events were mild to moderate in severity and did not differ statistically from the control group. All treatment-related adverse events resolved without complications.
Following the two-dose vaccination schedule, S4V2 induced immune responses with statistically significant increases in anti-LPS IgG antibody levels for all four targeted Shigella serotypes compared with the control group. Geometric Mean antibody Titers peaked after the second dose and remained above baseline levels six months later. Data from this trial provide encouraging evidence of immunogenicity and antibody persistence while highlighting the need for further evaluation of dose selection and vaccination scheduling to optimize the breadth and robustness of the immune response.
The Phase 2 CHIM trial S4V03 (Identifier: NCT06615375), aimed to evaluate the safety, immunogenicity and efficacy of S4V2 in approximately 120 healthy adults aged 18 to 50 years who were seronegative for Shigella at baseline. The trial was conducted across three clinical sites in the United States.